BioNTech’s BNT113 trial misses progression‑free survival endpoint, OS to be evaluated
BioNTech reported that its investigational mRNA cancer immunotherapy BNT113 combined with pembrolizumab failed to achieve a statistically significant improvement in progression‑free survival in the AHEAD‑MERIT Phase 2/3 trial for HPV‑16‑positive head and neck cancer. The independent data monitoring committee advised that the study continue to assess the second primary endpoint of overall survival, which could still deliver a positive outcome. The company noted that BNT113 received FDA Fast Track designation in January 2026.
Why it matters
The missed PFS result triggered a sell‑off in BioNTech shares, with pre‑market declines reported between 5% and 6% across sources, reducing the company’s market valuation. Continuation of the trial means investors must wait for the overall survival readout before reassessing the drug’s commercial potential.
Key facts
- 1The AHEAD‑MERIT Phase 2/3 trial did not meet its first dual primary endpoint of progression‑free survival for BNT113 plus pembrolizumab versus pembrolizumab alone. quiverquant.com
- 2The independent data monitoring committee recommended that the trial continue to evaluate the second dual primary endpoint of overall survival. quiverquant.com
- 3BNT113 received Fast Track designation from the U.S. Food and Drug Administration in January 2026. quiverquant.com
- 4Prof. Özlem Türeci, Co‑Founder and CMO, said the data support continued evaluation of BNT113 plus pembrolizumab and that the therapy is engaging its intended mechanism. investing.com
Open questions
- Material 4 reports a 1.16% decline to $95.84, while material 6 reports a 6.08% decline, material 7 a 5% decline, material 8 a 6% decline to $90.15, and material 11 a “nearly 6%” decline.
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.